Bristol Myers Squibb

Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research

Retrieved on: 
Tuesday, March 26, 2024
MGH, Harvard Medical School, Public health, Mass General Brigham, Massachusetts General Hospital, MDD, Patient, Public, Roche, Research, Merck, Social anxiety disorder, DSM-IV codes, Bristol Myers Squibb, Clinical trial, Neuropsychiatry, HMS, World Health Organization, Therapy, Hospital, Safety, WHO, SAD, Major depressive disorder, PTSD, Mass, Pharmaceutical industry

Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).

Key Points: 
  • Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).
  • “We continue to observe very significant need in the neuropsychiatric patient population,” said Dr. Eric Finzi, Co-Founder of Healis Therapeutics.
  • “MDD remains a public health challenge around the world,” said Erik Van Widenfelt, Head of Clinical Trials at Healis Therapeutics.
  • General Hospital (MGH) and Harvard Medical School,” said Sebastian De Beurs, Co-Founder of Healis Therapeutics.

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Depression, Eli Lilly, Major depressive disorder, Patient, Bristol Myers Squibb, PureTech Health, PRTC, Therapy, Creativity, Disorder, General counsel, CNS, Life, DSM-IV codes, Pleasure, Pharmacokinetics, Interim, Third Rock Ventures, U.S. FDA, Schizophrenia, KarXT, Teva Pharmaceuticals, ARCH Venture Partners, Merck, Anxiety, Merck & Co., Research and development, FDA, Lymphatic system, Hepatotoxicity, Sirna Therapeutics, Generalized anxiety disorder, Growth, Neuropsychiatry, Partner, Multimedia, Eli Lilly and Company, Probability, Liver, Medicine, Pharmaceutical industry

Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.

Key Points: 
  • Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.
  • Under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.
  • Eric Elenko, Ph.D., a PureTech co-founder and current Chief Innovation Officer, has been promoted to the role of President of PureTech.
  • Daphne Zohar, the Chief Executive Officer of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics.

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Health, Neurology, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Depression, Eli Lilly, U.S. FDA, Schizophrenia, KarXT, Major depressive disorder, ARCH Venture Partners, Patient, CNS, Anxiety, Bristol Myers Squibb, PureTech Health, DSM-IV codes, Pleasure, Neuropsychiatry, Research and development, Therapy, Pharmacokinetics, Partner, Disorder, Third Rock Ventures, Probability, FDA, Lymphatic system, Hepatotoxicity, Liver, Medicine, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.
  • The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health.
  • Seaport is advancing a clinical-stage pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms.
  • I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.”

KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Survival, Colorectal cancer, Cetuximab, Progression-free survival, Patient, FACP, Bristol Myers Squibb, University, MD Anderson Cancer Center, AACR, Pacific Time Zone, CRC, FDA, PDUFA, Pharmaceutical industry

The data will also be published simultaneously in Cancer Discovery .

Key Points: 
  • The data will also be published simultaneously in Cancer Discovery .
  • The safety profile for KRAZATI plus cetuximab was manageable and consistent with previous reports, and with the known safety profile of each drug individually.
  • In previous studies, treatment with cetuximab as a single agent did not offer a clinical benefit in patients with KRAS-mutated colorectal cancer.
  • KRAZATI is a registered trademark of Mirati Therapeutics, Inc., a Bristol Myers Squibb company.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

Retrieved on: 
Saturday, March 23, 2024
BMY, Bristol Myers Squibb, News, LLP, Death, Pomerantz, Food, Pharmaceutical industry

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company (“Bristol Myers” or the “Company”) (NYSE: BMY).

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company (“Bristol Myers” or the “Company”) (NYSE: BMY).
  • Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Ovarian cancer, Head, Uterine cancer, GSK, Patient, Dendreon, Commercial, Cancer, Bristol Myers Squibb, Neoplasm, Melanoma, TCR, Therapy, Research, MAGEA4, Sarcoma, GMP, Safety, Pharmacokinetics, Amgen, QC, CDMO, Development, Prevalence, Half-life, RECIST, Senior, FDA, Lung cancer, Administration, Conference, Entrepreneurship, Bank, Corr, Messenger, Protein, Pharmacology, Uveal melanoma, Pharmaceutical industry

“Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.

Key Points: 
  • “Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.
  • For IMA203CD8 GEN2, Immatics cleared dose level 4a (DL4a, up to ~1.6x109 TCR-T cells) in December 2023, which is currently intended to be the target dose for further development.
  • A next data update for both Phase 1b cohorts with IMA203 GEN1 and IMA203CD8 GEN2 is planned for 2H 2024.
  • On September 11, 2023, Immatics announced a strategic multi-platform collaboration with Moderna, combining Immatics’ target and TCR platforms with Moderna’s cutting-edge mRNA technology.

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
Employment, Development, ARVN, PROTAC, Pfizer, Oncology, Partnership, Novartis, Executive, Patient, Knowledge, National Cancer Institute, Bristol Myers Squibb, BMS, Neuroscience, Columbia University, LRRK2, Pharmaceutical industry

Effective today, Dr. Berkowitz will lead the ongoing clinical development of Arvinas’ PROTAC® protein degrader programs in oncology and neuroscience.

Key Points: 
  • Effective today, Dr. Berkowitz will lead the ongoing clinical development of Arvinas’ PROTAC® protein degrader programs in oncology and neuroscience.
  • “We are thrilled to have Dr. Berkowitz join Arvinas as we continue advancing multiple programs with the goal of improving the lives of patients with serious diseases,” said John Houston, Ph.D., Chairperson, President and Chief Executive Officer at Arvinas.
  • Dr. Berkowitz joins Arvinas from Bristol-Myers Squibb (BMS), where he was Senior Vice President, Development Unit Head, Hematology.
  • The option and restricted stock units were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock incentive plan.

Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma

Retrieved on: 
Monday, March 18, 2024
MC1R, BMY, Patient, Bristol Myers Squibb, Perspective, Therapy, Cancer, Nivolumab, Safety, Melanoma, CATX, PD-1, Pharmaceutical industry

This combination study is an amendment to the Company’s ongoing Phase1/2a study of [212Pb]VMT01 in patients with metastatic melanoma.

Key Points: 
  • This combination study is an amendment to the Company’s ongoing Phase1/2a study of [212Pb]VMT01 in patients with metastatic melanoma.
  • The study has completed enrollment in the first cohort and has commenced dosing in the second cohort.
  • Under the terms of the collaboration, Perspective will sponsor and fund the combination study and Bristol Myers Squibb will provide nivolumab for use in the study.
  • “We see great potential for synergistic treatment effect with our novel, systemically delivered, MC1R-targeted alpha-particle radioligand therapy, [212Pb]VMT01, in combination with nivolumab, a well-studied immunotherapy,” commented Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

Retrieved on: 
Friday, March 15, 2024
Prior, Bristol Myers Squibb, News, LLP, Death, Pomerantz, Food, Pharmaceutical industry

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company (“Bristol Myers” or the “Company”) (NYSE: BMY).

Key Points: 
  • NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company (“Bristol Myers” or the “Company”) (NYSE: BMY).
  • Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, March 14, 2024
EGFR, Gene editing, Cell, Immunotherapy, Patient, BMS, SLE, Bristol Myers Squibb, Protein engineering, IND, Investment, Therapy, CRS, Lymphoma, Research, Computational biology, ASH, Pharming, Investigational New Drug, IPSC, Cancer, Safety, Inflammation, Food, Cetuximab, AACR, Research and development, GAAP, NK, FDA, Administration, Ink, MBA, Abstract, Society, Rejection, Century, Autoimmunity, Pharmaceutical industry

PHILADELPHIA, March 14, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today reported financial results and business highlights for the full year ended December 31, 2023.

Key Points: 
  • In December 2023, Century presented initial clinical data from the Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory (r/r) B-cell lymphomas.
  • Data showed that CNTY-101 was well-tolerated at Dose Level 1 (100 million cells) in high-risk, heavily pretreated R/R B-cell lymphoma patients.
  • Net Loss: Net loss was $136.7 million for the year ended December 31, 2023, compared to $131.0 million for the year ended December 31, 2022.
  • The Company expects full year generally accepted accounting principles (GAAP) operating expenses to be between $135 million and $145 million.